X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with FDC LTD. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES FDC LTD. ALKEM LABORATORIES/
FDC LTD.
 
P/E (TTM) x - 24.4 - View Chart
P/BV x 7.6 5.1 150.1% View Chart
Dividend Yield % 0.6 0.9 61.0%  

Financials

 ALKEM LABORATORIES   FDC LTD.
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
FDC LTD.
Mar-14
ALKEM LABORATORIES/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs1,589144 1,107.3%   
Low Rs1,23279 1,559.5%   
Sales per share (Unadj.) Rs417.547.6 877.7%  
Earnings per share (Unadj.) Rs56.37.6 739.8%  
Cash flow per share (Unadj.) Rs64.79.0 718.2%  
Dividends per share (Unadj.) Rs12.702.25 564.4%  
Dividend yield (eoy) %0.92.0 44.5%  
Book value per share (Unadj.) Rs292.947.5 616.3%  
Shares outstanding (eoy) m119.57177.83 67.2%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.42.3 144.5%   
Avg P/E ratio x25.114.6 171.4%  
P/CF ratio (eoy) x21.812.3 176.5%  
Price / Book Value ratio x4.82.3 205.7%  
Dividend payout %22.629.6 76.3%   
Avg Mkt Cap Rs m168,65319,784 852.5%   
No. of employees `000NANA-   
Total wages/salary Rs m9,1711,221 751.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m49,9158,459 590.1%  
Other income Rs m1,645394 418.0%   
Total revenues Rs m51,5618,852 582.5%   
Gross profit Rs m8,4822,070 409.7%  
Depreciation Rs m1,006249 403.8%   
Interest Rs m67131 2,162.5%   
Profit before tax Rs m8,4512,184 387.0%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606606 265.2%   
Profit after tax Rs m6,7311,353 497.4%  
Gross profit margin %17.024.5 69.4%  
Effective tax rate %19.027.7 68.5%   
Net profit margin %13.516.0 84.3%  
BALANCE SHEET DATA
Current assets Rs m27,0624,355 621.3%   
Current liabilities Rs m15,3241,792 855.2%   
Net working cap to sales %23.530.3 77.6%  
Current ratio x1.82.4 72.7%  
Inventory Days Days6744 149.6%  
Debtors Days Days4125 167.4%  
Net fixed assets Rs m12,6103,025 416.8%   
Share capital Rs m239179 133.9%   
"Free" reserves Rs m34,4908,243 418.4%   
Net worth Rs m35,0278,453 414.4%   
Long term debt Rs m1,21211 11,323.4%   
Total assets Rs m54,38710,557 515.2%  
Interest coverage x13.671.4 19.0%   
Debt to equity ratio x00 2,732.7%  
Sales to assets ratio x0.90.8 114.5%   
Return on assets %13.613.1 103.8%  
Return on equity %19.216.0 120.0%  
Return on capital %24.923.5 105.7%  
Exports to sales %12.913.3 97.3%   
Imports to sales %3.13.3 92.3%   
Exports (fob) Rs m6,4611,126 574.0%   
Imports (cif) Rs m1,540283 544.7%   
Fx inflow Rs m6,5631,146 572.7%   
Fx outflow Rs m3,012355 847.6%   
Net fx Rs m3,552791 449.1%   
CASH FLOW
From Operations Rs m7,2591,485 488.8%  
From Investments Rs m1,864-620 -300.9%  
From Financial Activity Rs m-9,273-753 1,232.3%  
Net Cashflow Rs m-150113 -133.0%  

Share Holding

Indian Promoters % 66.9 68.9 97.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 4.7 704.3%  
FIIs % 0.0 7.5 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 19.0 -  
Shareholders   68,381 23,730 288.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   CIPLA  PFIZER  NATCO PHARMA  SHASUN PHARMA  PIRAMAL ENTERPRISES  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; IT Stocks Top Gainers(01:30 pm)

After opening the day marginally higher, share markets in India continued the momentum and are presently trading in green. Sectoral indices are trading on a mixed note, with stocks in the IT sector.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 22, 2018 03:33 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS